AGP Picks
View all

Chronic pruritus therapeutics market seen growing 7% a year through 2030

2 hours ago
Chronic pruritus therapeutics market seen growing 7% a year through 2030
By AI, Created 14:30 UTC, Nov 18, 2026, AGP -

The chronic pruritus therapeutics market is projected to rise from $10.91 billion in 2025 to $15.33 billion by 2030, driven by more biologic drugs, higher healthcare spending and stronger demand for long-term itch relief. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - The chronic pruritus therapeutics market is on a steady growth path as more patients seek durable relief for persistent itching and more treatment options reach the market. - The forecast points to rising demand for dermatology care, biologic therapies and personalized treatment approaches through 2030. - Higher healthcare spending is helping expand access to diagnosis, specialist visits and newer therapies.

What happened: - The Business Research Company projected the chronic pruritus therapeutics market will grow from $10.91 billion in 2025 to $11.7 billion in 2026. - The same report expects the market to reach $15.33 billion by 2030, implying a 7.0% CAGR over the forecast period. - The report describes chronic pruritus as persistent itching lasting six weeks or longer. - The company said the market has recently grown on the back of treatment advances and greater awareness of dermatological conditions. - The report is titled Chronic Pruritus Therapeutics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - A free sample is available here. - The full report is available here.

The details: - Historical growth was driven by rising chronic skin conditions, wider use of topical corticosteroids, better diagnostic accuracy, more dermatology specialist visits and broader availability of antihistamines. - Forecast growth is linked to more biologic drug approvals, higher dermatology research spending, greater focus on immune-related itch pathways, expanded access to online pharmacies and stronger patient demand for long-term relief. - The report highlights broader use of targeted biologic therapies, personalized treatment strategies, new anti-itch compounds, combination therapies and longer-term symptom control as key trends. - Chronic pruritus treatment is typically tailored to the cause of the itch and adjusted based on patient response. - Increasing healthcare expenditure is expected to support the market by improving access to specialized dermatology care and advanced treatments. - The Centers for Medicare & Medicaid Services reported in December 2024 that U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person.

Between the lines: - The forecast suggests the market is shifting from broad symptom management toward more targeted and sustained therapies. - The emphasis on biologics and immune pathways signals a move toward more precise treatment for patients who do not respond well to standard options. - Faster growth in Asia-Pacific points to expanding treatment access and unmet demand outside the largest current market. - The report’s expanded analytics, TAM analysis, scoring tools and forecasting dashboards suggest the industry is becoming more data-driven for investors and strategists.

What’s next: - North America held the largest market share in 2025, but Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The company listed contact details for further information, including Saumya Sahay at marketing@tbrc.info and multiple regional phone numbers.

The bottom line: - Chronic pruritus therapeutics is moving from a niche dermatology segment into a larger, faster-growing market built on biologics, better diagnosis and rising demand for lasting itch control.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.